Kalydeco Europeiska unionen - svenska - EMA (European Medicines Agency)

kalydeco

vertex pharmaceuticals (ireland) limited - ivacaftor - cystisk fibros - andra andningsorganprodukter - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 och 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 och 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Orkambi Europeiska unionen - svenska - EMA (European Medicines Agency)

orkambi

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cystisk fibros - andra andningsorganprodukter - orkambi tabletter är indicerat för behandling av cystisk fibros (cf) hos patienter i åldern 6 år och äldre och som är homozygot för den f508del mutation i cftr-genen. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Kaftrio Europeiska unionen - svenska - EMA (European Medicines Agency)

kaftrio

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystisk fibros - andra andningsorganprodukter - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Symkevi Europeiska unionen - svenska - EMA (European Medicines Agency)

symkevi

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystisk fibros - andra andningsorganprodukter - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Rogaine 50 mg/g Kutant skum Sverige - svenska - Läkemedelsverket (Medical Products Agency)

rogaine 50 mg/g kutant skum

mcneil sweden ab - minoxidil - kutant skum - 50 mg/g - butylhydroxitoluen hjälpämne; glycerol hjälpämne; minoxidil 50 mg aktiv substans; stearylalkohol hjälpämne; cetylalkohol hjälpämne; etanol, vattenfri hjälpämne - minoxidil

Lotorin 50 mg/g Kutant skum Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lotorin 50 mg/g kutant skum

ioulia and irene tseti pharmaceutical laboratories s.a. - minoxidil - kutant skum - 50 mg/g - stearylalkohol hjälpämne; glycerol hjälpämne; cetylalkohol hjälpämne; butylhydroxitoluen hjälpämne; etanol, vattenfri hjälpämne; minoxidil 50 mg aktiv substans

Rogaine 20 mg/ml Kutan lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

rogaine 20 mg/ml kutan lösning

mcneil sweden ab - minoxidil - kutan lösning - 20 mg/ml - minoxidil 20 mg aktiv substans; propylenglykol hjälpämne; etanol, vattenfri hjälpämne - minoxidil

Recrea 20 mg/ml Kutan lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

recrea 20 mg/ml kutan lösning

meda otc ab - minoxidil - kutan lösning - 20 mg/ml - propylenglykol hjälpämne; etanol, vattenfri hjälpämne; minoxidil 20 mg aktiv substans - minoxidil

Minoxidil Orifarm 20 mg/ml Kutan lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

minoxidil orifarm 20 mg/ml kutan lösning

orifarm generics a/s - minoxidil - kutan lösning - 20 mg/ml - minoxidil 20 mg aktiv substans; propylenglykol hjälpämne; etanol, vattenfri hjälpämne - minoxidil

Rogaine forte 50 mg/ml Kutan lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

rogaine forte 50 mg/ml kutan lösning

mcneil sweden ab - minoxidil - kutan lösning - 50 mg/ml - minoxidil 50 mg aktiv substans; propylenglykol hjälpämne; etanol, vattenfri hjälpämne - minoxidil